Mots-c Injection

The core pathological mechanism of diabetes lies in insulin resistance and glucose metabolic imbalance. By targeting and activating the AMPK signaling pathway, it has emerged as a potential candidate preparation for diabetes intervention. As the core regulatory pathway of energy metabolism in the body, activation of the AMPK pathway directly promotes glucose uptake and utilization in skeletal muscle cells, while inhibiting hepatic gluconeogenesis, thereby reducing blood glucose levels at the source. Preclinical studies have demonstrated that after administering it to diabetic model mice, the fasting blood glucose and glycated hemoglobin levels of the mice decreased significantly, the insulin resistance index was markedly reduced, and the expression level of glucose transporter 4 in skeletal muscle was significantly elevated, confirming its ability to effectively improve the sensitivity of peripheral tissues to insulin.

More clinically valuable is that MOTS-c Injection can concurrently prevent and control diabetes complications, especially exerting a protective effect on diabetic cardiomyopathy. Long-term hyperglycemia in diabetic patients tends to induce myocardial remodeling and decreased cardiac function. It can reduce oxidative stress damage in cardiomyocytes and improve myocardial energy metabolism efficiency by regulating mitochondrial function. Studies have found that it can inhibit the expression of inflammatory factors in the myocardial tissue of diabetic mice, alleviate the degree of myocardial fibrosis, and enhance myocardial systolic and diastolic functions, providing a new therapeutic target for the treatment of diabetic cardiomyopathy. In addition, for model animals with diabetes complicated by peripheral neuropathy, it can alleviate symptoms of nerve demyelination by improving blood supply and metabolism in nerve tissues, further expanding its application potential in the comprehensive management of diabetes.

First, enhancing energy expenditure-MOTS-c can activate the expression of thermogenesis-related genes in brown adipose tissue, promote the browning of white adipose tissue, and increase the basal metabolic rate of the body, enabling increased energy consumption even at rest.Second, promoting fatty acid oxidation-it accelerates the catabolism of fatty acids in adipocytes by upregulating the expression of key lipid metabolism genes such as PPARα, reducing fat accumulation in the liver, abdominal cavity, and other parts. Third, maintaining muscle mass-as a mitochondria-derived peptide, it can protect the mitochondrial function of skeletal muscle cells, inhibit muscle protein degradation, and preserve muscle mass and strength during weight loss.

Preclinical experimental data show that after 8 weeks of the product, the weight gain of obese model mice was reduced by more than 30% compared with the control group, the amount of abdominal and subcutaneous fat decreased significantly, while the skeletal muscle weight showed no obvious decline, and serum lipid indicators such as triglycerides and cholesterol returned to near-normal levels. This characteristic makes it particularly suitable for the adjuvant treatment of obesity-related metabolic syndrome. Since patients with metabolic syndrome are often accompanied by multiple disorders such as obesity, hyperlipidemia, and insulin resistance, it can synergistically improve multiple metabolic indicators with a single preparation, breaking the vicious cycle of "obesity-insulin resistance".In addition, it can mimic the regulatory effect of exercise on metabolism. For obese patients with sedentary lifestyles or limited exercise capacity, the injection form can conveniently replace part of the metabolic benefits of exercise, improving the feasibility of intervention.

Metabolic syndrome is a cluster of metabolic disorders characterized by obesity, hypertension, hyperglycemia, and hyperlipidemia. Its pathogenesis is complex, and single-target drugs are difficult to achieve comprehensive intervention. With the advantage of multi-pathway regulation, it can realize comprehensive regulation of metabolic syndrome. As mentioned above, on the basis of improving insulin resistance, controlling weight, and regulating blood lipids, it can also reduce blood pressure in hypertensive model animals by regulating vascular endothelial function, and decrease the risk of atherosclerosis.

In essence, as an exercise-induced mitochondrial-encoded regulator, it can mimic the beneficial effects of exercise on systemic metabolism, and exercise itself is a first-line intervention for metabolic syndrome. Studies have found that the level of endogenous it in human skeletal muscle and plasma increases significantly after exercise-the relative level of it in skeletal muscle can reach 11.9 times that before exercise, and remains at a high level even after 4 hours of rest, which also explains why it can replace part of the metabolic benefits of exercise. For patients with metabolic syndrome who cannot adhere to regular exercise, MOTS-c Injection can be used as an adjuvant intervention to achieve metabolic regulation through exogenous supplementation. Meanwhile, its mild side effect profile is superior to traditional metabolic drugs, providing a safety guarantee for long-term intervention.

At present, most studies on it in the field of metabolic disease treatment are in the preclinical stage, but the experimental results obtained have fully confirmed its potential value. Its unique advantages lie in being a mitochondria-derived peptide endogenous to the body, with high biocompatibility, and the ability to achieve synergistic regulation of glucose, lipid, and muscle metabolism, avoiding the limitations of single-target drugs. In the future, with the advancement of clinical research, it is necessary to further clarify the optimal dosage, administration frequency, and long-term safety in humans, and explore the combined application effect with existing metabolic drugs to improve therapeutic efficacy.

In addition, the application of the product in age-related metabolic decline is also worthy of attention. It can improve the metabolic function and exercise capacity of elderly animals, delay the occurrence of age-related metabolic disorders, which provides a new direction for the prevention and control of metabolic diseases in the elderly population. It is believed that with the deepening of research, it will gradually move from basic research to clinical application, becoming a new preparation in the field of metabolic disease treatment, and providing effective solutions to the growing global demand for the prevention and control of metabolic diseases.

The chemical stability of it is significantly affected by environmental factors. It can exist stably under neutral and weakly acidic conditions, while alkaline environments (pH>8.0) will accelerate its hydrolysis. As an injectable preparation, it avoids the degradation of peptide bonds by gastrointestinal digestive enzymes that occurs with oral administration. After subcutaneous or intraperitoneal injection, it can maintain a stable plasma concentration in the blood, with a half-life of approximately 2–4 hours.

Its metabolism in vivo is mainly achieved through hydrolysis into amino acid residues by peptidases, which then participate in the normal metabolic cycle of the body. No obvious toxic metabolites are produced. This characteristic endows it with favorable biocompatibility, with side effects limited to mild irritation at the injection site, consistent with the low-toxicity feature of its chemical structure.

The aforementioned chemical properties determine the administration route, storage conditions, and biosafety of the product, providing chemical-level support for its application in the treatment of metabolic diseases.